EMHTF - Emerald Health Therapeutics, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
2.0300
+0.0300 (+1.50%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close2.0000
Open1.9600
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.9500 - 2.1000
52 Week Range1.6900 - 7.7700
Volume165,716
Avg. Volume487,998
Market Cap288.504M
Beta (3Y Monthly)3.40
PE Ratio (TTM)N/A
EPS (TTM)-0.13
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Say What? A Marijuana Stock Buying Back Its Shares
    Motley Fool4 days ago

    Say What? A Marijuana Stock Buying Back Its Shares

    This newly public pot stock just announced a $50 million share buyback.

  • GlobeNewswire4 days ago

    Emerald Health Sees License Expansion of Pure Sunfarms Cannabis Production Operation to 687,000 Square Feet, one of Largest Production Capacities in Canada

    OTCQX:EMHTF) announced that its 50%-owned joint venture for large-scale, low-cost, high-quality cannabis production, Pure Sunfarms, received from Health Canada the fifth amendment to its cultivation license for its 1.1 million square foot greenhouse in Delta, BC. With an added approximately 137,000 square feet (half of Quadrant 3), the total licensed cannabis production area is approximately 687,000 square feet. The newly licensed area is expected to be fully planted by the end of this week.

  • GlobeNewswire7 days ago

    Emerald Health Therapeutics Closes $10.8 Million Prospectus Sale

    OTCQX:EMHTF) ("Emerald" or the “Company”) closed today its prospectus sale (the “Offering”) to a single Canadian institutional accredited investor (the “Investor”) announced on December 3, 2018. Pursuant to the Offering, the Company has issued 4,000,000 common shares of the Company (the "Common Shares") at a price per Common Share of $2.70, for gross proceeds of $10.8 million. The Investor has an option (the “Option”) to acquire up to a maximum of 1,555,555 additional Common Shares at a price per Common Share of $2.70 for a period of ten business days from the closing date.

  • 3 Events That Defined Pot Stock Emerald Health Therapeutics' 2018
    Motley Fool10 days ago

    3 Events That Defined Pot Stock Emerald Health Therapeutics' 2018

    This has been a big year for production and product line expansion, but it doesn't necessarily make this marijuana stock a buy.

  • GlobeNewswire10 days ago

    Emerald Joint Venture Receives Licenses from Health Canada to Sell Proprietary Products Supporting the Endocannabinoid System

    OTCQX: EMHTF) today announced that its joint venture, Emerald Health Naturals (“EHN”), has received product licenses and natural product numbers (NPNs) from Health Canada to sell its award-winning Endo product line of endocannabinoid-supporting nutritional products in Canada. The Endo product line has been designed to impact stress, anxiety, restless sleep, pain and other conditions using non-cannabis ingredients.

  • GlobeNewswire11 days ago

    Emerald Health Therapeutics Announces $10.8 Million Prospectus Sale

    Emerald Health Therapeutics, Inc. (EMH.V) ("Emerald" or the “Company”) has entered into a binding term sheet with a single Canadian institutional accredited investor (the “Lead Investor”) under which the Lead Investor has agreed, subject to certain customary conditions, to purchase 4,000,000 common shares of the Company (the "Common Shares") at a price of $2.70 per Common Share for gross proceeds of $10,800,000 (the "Offering"). The Offering may be increased by an additional 600,000 Common Shares for total aggregate gross proceeds of up to $12,420,000.

  • Canopy Growth to Get Extract Supply from MediPharm Labs
    Market Realist14 days ago

    Canopy Growth to Get Extract Supply from MediPharm Labs

    On November 29, Canopy Growth (WEED) entered an 18-month supply agreement with MediPharm Labs, in which the latter will supply up to 900 kilograms of cannabis extract to Canopy Growth and its subsidiaries for sale. Initially, Canopy Growth committed to a minimum purchase of 450 kilograms, which could later be extended to another 450 kilograms.

  • GlobeNewswire14 days ago

    Emerald Health Therapeutics Reports 3rd Quarter 2018 Financial Results and Provides Corporate Update

    OTCQX:EMHTF) (“Emerald” or “the Company”) has filed its financial statements and management discussion and analysis for the three and nine months ended September 30, 2018. “During the third quarter, we’ve fulfilled our initial supply scheduling, product, and volume commitments to our provincial cannabis distribution customers to participate in the adult-use cannabis market – demonstrating our ability to provide consistent and increasing contracted shipments of Emerald product,” said Avtar Dhillon, MD, President of Emerald Health Therapeutics.

  • GlobeNewswire16 days ago

    Emerald Health Therapeutics Announces Executive Chairman Avtar Dhillon Appointed as President; CEO Chris Wagner Steps Down

    OTCQX:EMHTF) announced today that Dr. Avtar Dhillon, Executive Chairman, has been appointed President of Emerald and that Chris Wagner has stepped down as CEO. As Executive Chairman, Dr. Dhillon has been intimately involved in setting the Company’s strategy and overseeing its operations.

  • ACCESSWIRE18 days ago

    Emerald Health is a Leader in the Canadian Cannabis Market with Huge Growing Capacity Planned

    NEW YORK, NY / ACCESSWIRE / November 26, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Emerald Health Therapeutics, Inc. (EMHTF), a licensed Canadian producer of cannabis. From an industry perspective, the recent legalization of cannabis sales for adult recreational use in Canada was a watershed moment for the entire industry and the Company.

  • November Update: Analysts’ Views of Supreme Cannabis
    Market Realist22 days ago

    November Update: Analysts’ Views of Supreme Cannabis

    Supreme Cannabis (SPRWF) is among the worst performers in the sector so far this year. The company’s stock closed nearly 39% lower YTD, which is similar to Emerald Health (EMHTF), which declined by nearly 43% so far this year as of November 19. Let’s look at how the analysts’ price targets and recommendations have changed in November.

  • GlobeNewswire22 days ago

    Emerald Health Therapeutics Appoints Agro-Biotech President

    VICTORIA, British Columbia, Nov. 22, 2018 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced that Thierry Schmidt has been.

  • GlobeNewswire25 days ago

    Emerald Health Therapeutics Receives TSX Venture Conditional Approval of Emerald Health Naturals Joint Venture

    OTCQX:EMHTF)  is pleased to announce that it has received conditional approval of the TSX Venture Exchange regarding its 51:49 joint venture (the “Joint Venture”) with San Diego-based Emerald Health Bioceuticals (“EHB”), to be called Emerald Health Naturals (“EHN”). The Company will invest $5,000,000 for 51% equity ownership of EHN.

  • GlobeNewswirelast month

    MediPharm Labs Corp. Receives Sales Licence from Health Canada

    MediPharm Labs Corp. (“MediPharm Labs” or the “Company”) (LABS.V) is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc., has received its sales licence from Health Canada (the “Sales Licence”) pursuant to the Cannabis Act. “This Sales Licence represents a significant milestone for MediPharm Labs and a key component of our strategy to be a producer of cannabis concentrates at a globally-recognized quality standard, while also being focused on revenues, profitability and value to our shareholders, partners and constituents,” says Pat McCutcheon, co-founder and CEO of MediPharm Labs.

  • ACCESSWIRElast month

    Marijuana Stocks Rally Into Thursday Morning After Sessions News: Integrated Cannabis Company (OTC: ICNAF) (CSE: ICAN), Aphria, Emerald Health

    CORAL GABLES, FL / ACCESSWIRE / November 8, 2018 / Marijuana stocks have seen a surge of attention this year. This event has been well received by the public markets as many marijuana stocks have positively reacted to this news. Sessions, who has been a staunch adversary of the legalization of cannabis, took a very conservative approach when broaching the subject.

  • ACCESSWIRElast month

    Cannabis and Stem Cells Firms That Could Explode

    HENDERSON, NV / ACCESSWIRE / November 8, 2018 / A major stem cell report was released today. Scientists have created a tiny, biodegradable scaffold to transplant stem cells and deliver drugs, which may ...

  • GlobeNewswirelast month

    Emerald Health Therapeutics Fulfilling Supply Commitments with Provincial Adult-Use Cannabis Shipments

    OTCQX:EMHTF) has completed its first shipments of adult-use cannabis, fulfilling its initial supply scheduling, product, and volume commitments in British Columbia and Newfoundland and Labrador – an important milestone for the Company as it significantly ramps up production and sourcing of cannabis and cannabinoid products. Emerald products have been available in these provinces since October 31st.

  • 3 Marijuana Growing Stocks With the Highest Risk
    Motley Foollast month

    3 Marijuana Growing Stocks With the Highest Risk

    There's more to investing in pot stocks than peak production estimates.

  • ACCESSWIRE2 months ago

    Stocks That Could Run Hyperbolic

    HENDERSON, NV / ACCESSWIRE / October 23, 2018 / We have several stocks on our radar for a big week. One that is jumping off the screen CleanSpark, Inc. (CLSK). If you look at their recent filings you'll ...

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Files 17 Patent Applications Covering Defined Dose™ Cannabis Products

    OTCQX:EMHTF) has filed 17 provisional US patent applications covering Emerald’s unique Defined Dose™ cannabis dosage forms and formulations. Based on proprietary Emerald research, these patent applications are contributing to Emerald’s intellectual property portfolio and its intent to develop distinctive cannabis products for medical-use and improved adult-use.  The products provide more precise and consistent delivery, dosage, and formulations.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Promotes Paul R. Dillman, Jr. to Executive Vice President of Global Sales and Marketing

    OTCQX:EMHTF) (“Emerald”) today announced the promotion of Paul R. Dillman, Jr. to Executive Vice President of Global Sales and Marketing. “Paul has been instrumental in preparing the Emerald brand for adult-use legalization in Canada,” said Chris Wagner, Chief Executive Officer of Emerald.

  • GlobeNewswire2 months ago

    MediPharm Labs Corp. and Emerald Health Therapeutics, Inc. Sign Cannabis Concentrate Program Agreement

    MediPharm Labs Corp. ("MediPharm") (LABS.V) is pleased to announce that it has entered into a Cannabis Concentrate Program Agreement (the "Agreement") with Emerald Health Therapeutics Inc. ("Emerald") (TSXV: EMH - OTCQX:EMHTF). Pursuant to the Agreement, signed on October 5, 2018, Emerald will provide MediPharm with dried cannabis to create premium quality cannabis oil (the "Program"). The Agreement enables Emerald to provide pharmaceutical grade cannabis concentrate products produced by MediPharm to its large base of registered patients, as well as provide adult-use recreational consumers with premium quality cannabis concentrates commencing October 17, 2018.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics’ Subsidiary Northern Vine Receives International Government Approvals and Completes Import and Export of Cannabis Oils for Research & Development

    OTCQX:EMHTF) (“Emerald”) announced today that Northern Vine Canada Inc. (Northern Vine), a wholly owned subsidiary of Emerald, successfully completed the export of cannabis oil to the United States on May 25 pursuant to an import permit from the federal U.S. Drug Enforcement Agency (DEA). The cannabidiol (CBD)-containing cannabis oil is expected to be used by a US biopharmaceutical company to develop its proprietary cannabinoid technology for medical research and development and for its manufacturing process for future clinical trials.

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics’ Wholly Owned Subsidiary Northern Vine to Participate in Series of Cannabis Testing Seminars Hosted by Thermo Fisher Scientific

    VICTORIA, British Columbia, Oct. 09, 2018 -- Emerald Health Therapeutics, Inc. (“Emerald”) (TSXV:EMH; OTCQX:EMHTF) (“Emerald”) today announced that Northern Vine Canada Inc..

  • GlobeNewswire2 months ago

    Emerald Health Therapeutics Enters Research Agreement with VivaCell Biotechnologies to Evaluate Proprietary Cannabis Products

    OTCQX:EMHTF) (“Emerald”) has entered into a research agreement with VivaCell Biotechnologies Spain S.L.U. (“VivaCell”). VivaCell is an institute focused on cannabis research, which will provide its cannabis-industry-leading contract research organization (CRO) services to Emerald to elucidate the mechanism of action of proprietary formulations and dosage forms that Emerald is developing. This collaboration has the potential to strengthen Emerald’s intellectual property portfolio and assist in establishing Emerald as a leader in the development of proprietary cannabis products for medical-use and improved adult-use products with more precise and consistent delivery, dosage, and formulations.